Epicardial Fat, Visceral Fat and Coronary Atherosclerosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

110 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-07-31

Study Completion Date

2012-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Background: Visceral fat is increasingly associated with metabolic syndrome and with fatty liver, a condition carrying a high risk of cardiovascular disease. The independent role of epicardial fat deposition in cardiovascular risk remains unclear.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Visceral Abdominal Fat, Non Alcoholic Fatty Liver Diseases and Asymptomatic Coronary Atherosclerosis

NCT01282892

Visceral Fat Fatty Liver Atherosclerosis +1 more

UNKNOWN

Visceral Adiposity and CVD Risk in Women

NCT00021879

Cardiovascular Diseases Heart Diseases Obesity +1 more

COMPLETED

Abdominal Fat and Imaging Measurements of Heart Disease

NCT01447745

Visceral Obesity Atherosclerosis Metabolic Syndrome

COMPLETED

Visceral Fat, Metabolic Rate, and CHD Risk in Young Adults

NCT00005388

Cardiovascular Diseases Heart Diseases Coronary Disease +1 more

COMPLETED

The Weight of Cardiovascular Disease

NCT06053645

Cardiovascular Diseases Obesity

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Background: Visceral fat is increasingly associated with metabolic syndrome and with fatty liver, a condition carrying a high risk of cardiovascular disease. The independent role of epicardial fat deposition in cardiovascular risk remains unclear. Aim: Evaluate the link between epicardial fat, visceral fat, liver fat accumulation and cardiovascular diseases and carotis atherosclerosis in patients with the major cardiovascular risk factors and with or without metabolic syndrome.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Epicardial Fat Visceral Fat Atherosclerosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

patient with liver fat

30 patients with liver fat

patient with liver fat

Intervention Type OTHER

30 patient with liver fat

excess of visceral fat

50 pts. with excess of visceral fat

pts. with excess of visceral fat

Intervention Type OTHER

pts. with excess of visceral fat

control

30 control subjects

control

Intervention Type OTHER

30 control subjects

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

patient with liver fat

30 patient with liver fat

Intervention Type OTHER

pts. with excess of visceral fat

Intervention Type OTHER

control

30 control subjects

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients referred to cardiac CT will be the source of recruitment.
* patients with excess of visceral fat,
* 30 patients with liver fat accumulation
* 30 sex-age-matched individual (controls) will be enrolled. All patients will undergo a complete family history, personal clinical history, physical examination and blood sampling for biochemical analysis.
* Informed consent will be obtained from each individual.

Exclusion Criteria

* subjects with severe morbid obesity (body mass index \[BMI\] \> 40),
* recent history of acute illness,
* clinical history of ischemic heart disease and cerebrovascular disease,
* typical chest pain,
* previous coronary artery disease,
* conventional coronary angiography, percutaneous interventions, coronary by pass grafting, renal failure, cancer patients,
* subjects who take drugs that induces hepatic steatosis ( corticosteroids, estrogens, methotrexate, amiodarone and others)

Minimum Eligible Age

40 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes